Sun Pharma’s big US bet is paying off. After spending over INR 4,688 crore to buy Concert Pharma, the company secured rights to Leqselvi for hair growth in alopecia areata patients. The drug has now received US FDA approval, but insiders say the real contest with global giants like Pfizer and Eli Lilly is only beginning.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
